Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors

References

• Gardner-RoehneltNMUpdate on the management of neuroendocrine tumors: focus on somatostatin antitumor effectsClin J Oncol Nurs2012161566422297008
   PubMedGoogle Scholar
• di BartolomeoMBajettaEBuzzoniRClinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology GroupCancer19967724024088625251
   PubMed Web of Science ®Google Scholar
• ObergKManagement of neuroendocrine tumoursAnn Oncol200415suppl 4iv293iv29815477324
   PubMedGoogle Scholar
• KvolsLKMoertelCGO’ConnellMJSchuttAJRubinJHahnRGTreatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogueN Engl J Med1986315116636662427948
   PubMedGoogle Scholar
• RubinJAjaniJSchirmerWOctreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndromeJ Clin Oncol199917260060610080605
   PubMed Web of Science ®Google Scholar
• RinkeAMullerHHSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• CaplinMEPavelMCwiklaJBLanreotide in metastatic enteropancreatic neuroendocrine tumorsN Engl J Med2014371322423325014687
   PubMed Web of Science ®Google Scholar
• BerardiRRinaldiSTorniaiMGastrointestinal neuroendocrine tumors: searching the optimal treatment strategy – a literature reviewCrit Rev Oncol Hematol20169826427426643525
   PubMed Web of Science ®Google Scholar
• SchmidHASchoeffterPFunctional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumorsNeuroendocrinology200480suppl 1475015477717
   PubMedGoogle Scholar
• de HerderWWHoflandLJvan der LelyAJLambertsSWSomatostatin receptors in gastroentero-pancreatic neuroendocrine tumoursEndocr Relat Cancer200310445145814713257
   PubMed Web of Science ®Google Scholar
• VillaumeKBlancMGouysseGVEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathwayNeuroendocrinology201091326827820389030
   PubMed Web of Science ®Google Scholar
• TulipanoGStummRPfeifferMKreienkampHJHölltVSchulzSDifferential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypesJ Biol Chem200427920213742138215001578
   PubMed Web of Science ®Google Scholar
• CescatoRSchulzSWaserBInternalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonistsJ Nucl Med200647350251116513620
   PubMed Web of Science ®Google Scholar
• LiMLiWKimHJYaoQChenCFisherWECharacterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCRJ Surg Res2004119213013715145694
   PubMedGoogle Scholar
• RongaGSalernoGProcacciniE111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in vivo evidence of the possible down-regulation of somatostatin receptorsQ J Nucl Med1995394 suppl 1134136
   PubMedGoogle Scholar
• PlockingerUWiedenmannBTreatment of gastroenteropancreatic neuroendocrine tumorsVirchows Arch2007451suppl 1S71S8017684765
   PubMedGoogle Scholar
• SchmidHAPasireotide (SOM230): development, mechanism of action and potential applicationsMol Cell Endocrinol20082861–2697417977644
   PubMed Web of Science ®Google Scholar
• ChenXShenGJiangJPharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized studyClin Ther20143681196121025012727
   PubMed Web of Science ®Google Scholar
• WolinEMJarzabBErikssonBPhase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analoguesDrug Des Devel Ther2015950755086
   PubMed Web of Science ®Google Scholar
• CivesMKunzPLMorseBPhase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumorsEndocr Relat Cancer20152211925376618
   PubMed Web of Science ®Google Scholar
• KulkeMRuszniewskiPVan CutsemEA randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialAnn Oncol Epub201736
   PubMedGoogle Scholar
• NeuenschwanderBBransonMGsponerTCritical aspects of the Bayesian approach to phase I cancer trialsStat Med200827132420243918344187
   PubMed Web of Science ®Google Scholar
• LoveJNHowellJMGlucagon therapy in the treatment of symptomatic bradycardiaAnn Emerg Med19972911811838998104
   PubMedGoogle Scholar
• BindonMJBarlottaKGlucagon treatment for bradycardia and a junctional rhythm caused by excessive beta-blockadeResuscitation20098011132719744763
   PubMedGoogle Scholar
• SinghBSmithJAAxelrodDMInsulin-like growth factor-I inhibition with pasireotide decreases cell proliferation and increases apoptosis in pre-malignant lesions of the breast: a phase 1 proof of principle trialBreast Cancer Res201416646325385439
   PubMedGoogle Scholar
• GutPCzarnywojtekAFischbachJChromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfallsArch Med Sci20161211926925113
   PubMed Web of Science ®Google Scholar
• BaudinEGigliottiADucreuxMNeuron-specific enolase and chromogranin A as markers of neuroendocrine tumoursBr J Cancer1998788110211079792158
   PubMed Web of Science ®Google Scholar